Oxonic Acid-13C2,15N3 (potassium salt hydrate)
(Synonyms: Allantoxanic Acid-13C2,15N3, Potassium oxonate-13C2,15N3) 目录号 : GC48933
An internal standard for the quantification of oxonic acid
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Oxonic acid-13C2,15N3 is intended for use as an internal standard for the quantification of oxonic acid (potassium salt) by GC- or LC-MS. Oxonic acid is a uricase inhibitor (IC50 = 0.8 µM) that prevents metabolism and excretion of uric acid.1,2 It also inhibits orotate phosphoribosyltransferase (ORPT), reducing OPRT-mediated phosphorylation of 5-fluorouracil in Yoshida sarcoma cell extracts with an IC50 value of 3.7 µM.3 Oxonic acid (10-50 mg/kg) decreases the severity of gastrointestinal tract injury and the incidence of diarrhea induced by the 5-FU prodrug tegafur and uracil without loss of antitumor activity in a rat Yoshida sarcoma model. It has also been used to induce hyperuricemia in rodents.4 Formulations containing oxonic acid have been used in the treatment of head, neck, lung, pancreatic, gastric, and breast carcinomas.
1.Johnson, W.J., and Chartrand, A.Allantoxanamide: A potent new uricase inhibitor in vivoLife Sci.23(22)2239-2244(1978) 2.Gralla, E.J., and Crelin, E.S.Oxonic acid and fetal development: I. Embryotoxicity in miceToxicology6(3)289-297(1976) 3.Shirasaka, T., Shimamoto, Y., and Fukushima, M.Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in ratsCancer Res.53(17)4004-4009(1993) 4.Stavric, B., and Nera, E.A.Use of the uricase-inhibited rat as an animal model in toxicologyClin. Toxicol.13(1)47-74(1978)
| Cas No. | SDF | ||
| 别名 | Allantoxanic Acid-13C2,15N3, Potassium oxonate-13C2,15N3 | ||
| Canonical SMILES | O=[13C]([15N]=C(C([O-])=O)[15NH]1)[15NH][13C]1=O.[K+].O | ||
| 分子式 | C2[13C]2H2[15N]3O4•K [XH2O] | 分子量 | 200.1 |
| 溶解度 | Water: slightly soluble | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.9975 mL | 24.9875 mL | 49.975 mL |
| 5 mM | 0.9995 mL | 4.9975 mL | 9.995 mL |
| 10 mM | 0.4998 mL | 2.4988 mL | 4.9975 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。